Janssen Pharmaceutica Nv

Phenex Pharmaceuticals Ag

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Aicuris Gmbh + Co. Kg.

Innovative Molecules Gmbg

Phenex Discovery Verwaltungs-gmbh

Innovative Molecules Gmbh

Bayer Healthcare Aktiengesellschaft

Martin Hendrix

Gerald Kleymann

Wolfgang Bender

Ulrich Betz

Ruediger Fischer

Tobias Laich

Christian Gege

Christoph Steeneck

Olaf Kinzel

Thomas Hoffmann

Steven D Goldberg

Hariharan Venkatesan

Kerstin Henninger

Judith Baumeister

Xiaohua Xue

Anne Fourie

Jörg Keldenich

Udo Schneider

Olaf Weber

Virginia M Tanis

Peter Eckenberg

Axel Jensen

Gabriele Handke

David A Kummer

Rudolf Schohe-Loop

Rüdiger Fischer

Aihua Wang

Rolf Grosser

Thomas Lampe

Tobias Wunberg

Maud J Urbanski

Joerg Keldenich

Mario Jeske

Peter Nell

Holger Zimmermann

Frank Süβmeier

Claus Kremoser

J&ouml;rg Keldenich

Tse-I Lin

Thomas Krämer

Guy Hewlett

Susanne Nikolic

Jürgen Reefschläger

Frank Suessmeier

R&uuml;diger Fischer

Thomas Schlüter

Michael Albers

Sanja Perovic-Ottstadt

Juergen Reefschlaeger

Simon Anderhub

Martin Hornberger

Anne M Fourie

Thomas Kraemer

Frank Süßmeier

The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomets, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.

Enantiomers of substituted thiazoles as antiviral compounds

The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.

The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof. 

Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

The invention relates to novel compounds of the Formula (I), to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments. 

Aminothiazole derivatives useful as antiviral agents

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100&#x2032;), (200) and (200&#x2032;) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof. 

Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[&#x3b3;]

The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R-1-carbonyl)thiazole-2-carboxamide, wherein Ris defined in the specification.

Trifluoromethyl alcohols as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I wherein:R, R, R, R, R, R, R, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Thiazoles as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I wherein:R, R, R, R, R, R, R, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

The present invention comprises compounds of Formula I. wherein:X, A, A, A, A, R, R, and Rare defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

The present invention comprises compounds of Formula I. wherein:R, R, R, R, A, A, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Amide substituted thiazoles as modulators of RORyt

The invention provides modulators for the orphan nuclear receptor RORand methods for treating RORmediated diseases by administrating these novel RORmodulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of Formula (1) and the enantiomers, diastereomers, N-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof. 

Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR&#x3b3;, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof. 

Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ROR&#x3b3;

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof. 

Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-&#x3b3; (ROR-&#x3b3;, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

The invention provides modulators for the orphan nuclear receptor ROR&#x3b3; and methods for treating ROR&#x3b3; mediated diseases by administrating these novel ROR&#x3b3; modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof. 

Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR&#x3b3;, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease

The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.

2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses

Growing community of inventors

Bad Salzuflen, Germany

Gerald Kleymann